news
Press release
 
October 13, 2016
Corindus Vascular Robotics Appoints Suzette Jaskie Vice President Global Medical Affairs

WALTHAM, MA - October 13, 2016Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced the appointment of Suzette Jaskie as Vice President Global Medical Affairs.

Ms. Jaskie has 30 years of healthcare experience, the majority of which has been spent specifically in the cardiovascular field. Most recently, she served as President and Chief Executive Officer of MedAxiom Consulting. Prior to MedAxiom, she served as Executive Director of the Frederik Meijer Heart & Vascular Institute, Grand Rapids, MI, where she worked with co-medical directors to conceive, build and manage the multidisciplinary entity formed of 98 cardiovascular physician specialists and hospital administrators to manage the regional cardiovascular service line of Spectrum Health.

As Vice President Global Medical Affairs at Corindus, Ms. Jaskie will develop and execute best in class medical education programs focusing on robotic therapy and drive strategy for scientific, medical and industry conferences.

"I am very pleased to welcome Suzette to Corindus. As a veteran of the cardiovascular industry, she brings extensive knowledge and hands-on experience with distinguished medical organizations. I am looking forward to partnering with her as we continue to prove the benefits of robotic therapy to physicians, patients and hospitals," said Corindus CEO, Mark J. Toland.

"I am thrilled to join Corindus at this transformational point in the company’s growth. I look forward to working with Mark, CMO Dr. Grantham, and the entire Corindus team to build centers of excellence and further educate the interventional cardiology community on the benefits of robotic therapy," said Ms. Jaskie.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.